Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04050436
Title Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Replimune Inc.
Indications

skin squamous cell carcinoma

Therapies

Cemiplimab + RP1

RP1

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU | CAN


No variant requirements are available.